Compare HTLD & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | OPK |
|---|---|---|
| Founded | 1978 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1995 | 2011 |
| Metric | HTLD | OPK |
|---|---|---|
| Price | $11.62 | $1.69 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $11.50 | $1.60 |
| AVG Volume (30 Days) | 596.4K | ★ 2.5M |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $805,709,000.00 | $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.36 | $4.24 |
| P/E Ratio | $166.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $0.98 |
| 52 Week High | $16.64 | $1.73 |
| Indicator | HTLD | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 66.07 |
| Support Level | $10.67 | $1.12 |
| Resistance Level | $12.13 | $1.73 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 14.93 | 82.69 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.